Saw Palmetto No Better Than Placebo for Enlarged Prostate
Saw palmetto, an herbal extract commonly taken to improve urinary symptoms in men with englarged prostate glands, is no more effective than a placebo.
Ads by Google
Saw palmetto, an herbal extract commonly taken to improve urinary symptoms in men with englarged prostate glands, is no more effective than a placebo.
The researchers discovered the novel virus far more often in human prostate tumors with two copies of the RNASEL gene mutation than in those with at least one normal copy.
Studies have shown a decrease in prostate cancer mortality since 1992 and some researchers attribute a portion of that fall to the widespread adoption of the PSA test.
Race plays a minor role in prostate cancer survival, and that the most important factors related were education, community poverty, and income levels.
A consortium of prostate cancer experts have discovered that prostate cancer patients who have a lower prostate specific antigen (PSA) score after radiation therapy to treat their cancer are less likely to have their prostate cancer return.
About half of men with an enlarged prostate seek medical treatment because of bothersome urinary tract symptoms.
While there is no medical benefit to postponing treatment for prostate cancer for six months, delaying treatment can allow a patient time to understand the options and pick the best.
The virus is 25 times more likely to be found in prostate cancer patients with a specific genetic mutation than men without the mutation.
Speed of PSA increase matters more than PSA level.
Prostate cancer in young men is not more aggressive and due to the lack of much concern it is recommended an active treatment approach in younger men.
Men with prostate cancer who experience bone loss from cancer treatment could benefit from a weekly oral therapy commonly given to women with osteoporosis.
A new radiation therapy for prostate cancer, Cesium 131 brachytherapy, has fewer side effects than other treatments.
Screening tests can increase the detection of prostate cancer, even at earlier stages, but not necessarily prolong prostate cancer survival.
Diagnosing prostate cancer is a bit like finding a needle in a haystack and doctors may be missing cancers in obese men.
A new line of prostate cancer cells may provide a better model to study the disease. It identified a possible therapy to reduce prostate cancer pain.
There is great potential for the use of biomarkers as a means of detecting and monitoring prostate cancer more effectively.
Early warning signs of possible prostate cancer are: difficulty urinating, and urinating very often at night.
Treating high risk prostate cancer patients with radiation therapy and adding hormone therapy for more than one year allows patients to live longer.
Prostate cancer is the most common type of cancer in U.S. men after skin cancer.
The data in our study provides tantalizing evidence that gene fusion is the causative agent in prostate cancer.
The finding of a fused gene in prostate cancer is creating a new frontier in developing tests for earlier detection of prostate cancer.
This discovery on prostate cancer could pave the way for development of a new molecularly targeted prostate cancer treatment.
Men with early prostate cancer who are obese have a greater risk of cancer progression following a prostatectomy.
Treatment of advanced, hormone refractory prostate cancer with the chemotherapy drug Taxotere and Quadramet reduces prostate specific antigen (PSA) levels.
Obesity may be closely associated with prostate cancer possibly increasing the odds of prostate cancer.
Pomegranate juice shows major promise to combat and treat prostate cancer.
Many men with relapsed prostate cancer will still have a median survival of more than a decade after being given hormonal treatment.
Men who eat plenty of tomato products, especially tomato sauce laden foods, have a lower risk of prostate cancer.
Research identified a panel of 22 biomarkers that together more accurately predicted prostate cancer than the PSA test.
Testing blood samples for antibodies that target prostate cancer cells may help identify patients with early stages of the disease.